Evaluating the Long-Term Impact of Antithrombotics in TBI

Managing acute traumatic head injuries in an aging society presents major clinical challenges. Today, many older patients receive chronic anticoagulation or antiplatelet agents for underlying cardiovascular indications. Consequently, clinicians frequently encounter antithrombotics in TBI presentations within emergency and neurotrauma units. Historically, medical teams feared that pre-injury antithrombotic therapy inevitably dictated devastating neurologic decline and rapid patient mortality. Furthermore, older studies frequently associated these medications with secondary hematoma expansion and catastrophic neurological deterioration. However, modern trauma systems utilize structured resuscitation bundles and targeted hemostatic reversal agents. Therefore, researchers need updated evidence to assess whether baseline anticoagulation truly impairs long-term functional recovery. Most prior studies only examined short-term inpatient survival or thirty-day mortality rates. As a result, critical knowledge gaps persisted regarding two-year functional outcomes among survivors of moderate-to-severe trauma. A landmark multi-center investigation has now evaluated these long-term functional endpoints. Specifically, the authors aimed to determine if chronic antithrombotic exposure independently limits long-term neurological independence. By tracking patients over two full years, this investigation provides vital clarity for neurosurgeons, trauma intensivists, and emergency physicians worldwide.

Propensity-Matched Case-Controlled Study Architecture

To examine long-term outcomes without confounding bias, researchers conducted a rigorous retrospective case-controlled study across two Level-1 trauma centers between 2017 and 2024. Overall, the investigators screened 664 consecutive cases of moderate-to-severe traumatic brain injury. However, patients on antithrombotic therapy often have older ages and extensive medical comorbidities. Therefore, the investigative team applied a 1:1 nearest neighbor propensity score matching protocol. Specifically, they utilized a strict 0.05 caliper to balance vital clinical covariates between cohorts. These balanced variables included patient age, sex, admission Glasgow Coma Scale score, polytrauma rates, and multicompartment intracranial hemorrhage. Following this rigorous matching procedure, the final analysis included 248 highly comparable patients. Among these individuals, 124 patients were receiving pre-injury antithrombotics, while 124 matched controls had no prior antithrombotic exposure. Within the active medication cohort, 20 patients received direct oral anticoagulants, 31 took vitamin K antagonists, 63 received antiplatelet monotherapy, and 10 used dual antithrombotic therapy. The researchers serially evaluated patients at hospital discharge, six months, one year, and two years. Consequently, this study design minimized baseline confounders and isolated the genuine impact of pharmacological anticoagulation on functional survival.

Acute Radiographic Severity Versus Functional Outcomes

Initial computed tomography imaging revealed striking differences in acute injury presentation between the matched cohorts. Specifically, patients receiving antithrombotic medications demonstrated significantly greater radiographic severity upon hospital arrival. These individuals more frequently displayed extensive multicompartment bleeding, expansive subdural hematomas, and rapid intraparenchymal hemorrhage progression. Accordingly, the antithrombotic cohort required higher rates of emergent neurosurgical interventions, approaching statistical significance. Nevertheless, these heightened early anatomic insults did not translate into worse survival or functional impairment. In fact, in-hospital mortality rates remained statistically equivalent between antithrombotic users and non-users. Moreover, early discharge disposition metrics, including direct discharge home, showed no significant divergence between the two study groups. Most importantly, long-term functional recovery, measured by the Glasgow Outcome Scale-Extended, demonstrated equivalent trajectories across both cohorts. The serial assessments at six months, one year, and two years confirmed durable functional equivalence among survivors. Thus, while pre-existing antithrombotic regimens increase initial radiological bleeding volumes, aggressive acute stabilization prevents these anatomical injuries from dictating permanent long-term disability. Consequently, clinicians must not view pre-injury anticoagulation as an automatic indicator of poor functional prognosis.

Comparative Risks: DOACs, VKAs, and Antiplatelet Therapies

In addition to evaluating the aggregate cohort, the researchers performed granular subgroup analyses across distinct pharmacological drug classes. Specifically, they compared functional recovery between direct oral anticoagulants, vitamin K antagonists, and antiplatelet therapy. Interestingly, functional independence scores remained remarkably comparable between patients taking direct oral anticoagulants and those receiving vitamin K antagonists across all follow-up intervals. However, distinct survival trajectories emerged when evaluating absolute mortality rates. Notably, patients in the vitamin K antagonist cohort demonstrated the highest mortality at every serial observation interval. Multiple physiological factors likely explain this persistent vulnerability. For instance, vitamin K antagonists induce broader coagulopathy and often require longer windows to achieve complete physiological reversal. In contrast, modern targeted reversal agents for direct oral anticoagulants permit rapid, predictable restoration of hemostatic competence. Antiplatelet agents presented a separate clinical challenge, showing significant radiographic bleeding despite absence of secondary systemic coagulopathy. Furthermore, patients on combination therapy with aspirin and warfarin exhibited high cumulative hemorrhage burdens. Nevertheless, surviving patients across all pharmacological subsets achieved similar functional trajectories once clinicians managed acute intracranial hemorrhage expansion.

The Decisive Role of Rapid Anticoagulation Reversal

Why did severe initial intracranial hemorrhage fail to worsen two-year functional outcomes in the antithrombotic cohort? The authors emphasized that aggressive, standardized resuscitation protocols within Level-1 trauma centers fundamentally altered patient trajectories. When emergency teams suspect antithrombotics in TBI presentations, they rapidly initiate established reversal protocols. In modern neurotrauma centers, clinicians urgently administer four-factor prothrombin complex concentrate, intravenous vitamin K, and specific direct reversal antidotes. Consequently, rapid hemostatic normalization promptly halts early hematoma expansion within the vulnerable brain parenchyma. Furthermore, timely neurosurgical decompression relieves intracranial hypertension before irreversible secondary brain ischemia occurs. By halting microscopic bleeding progression, these modern protocols effectively limit the volume of permanent tissue destruction. In contrast, historic cohorts experienced delayed recognition and prolonged coagulopathy, which frequently caused devastating neurological outcomes. In addition, aggressive intensive care management, continuous intracranial pressure monitoring, and structured neuro-rehabilitation further promote durable neuronal recovery. Therefore, modern evidence demonstrates that proactive therapeutic reversal can mitigate the theoretical excess risk posed by pre-existing antithrombotic medications. Coordinated trauma resuscitation bridges the initial pharmacological deficit and protects long-term neurological potential.

Clinical Implications for Emergency Trauma Practice

These clinical findings provide valuable pragmatic lessons for emergency physicians, intensivists, and neurosurgeons managing acute head injuries. First, medical teams must not allow pre-injury anticoagulation status to introduce unwarranted therapeutic nihilism. Although antithrombotic therapy accelerates initial bleeding on neuroimaging, patients can still achieve high levels of functional independence over two years. Second, trauma centers must maintain rapid, protocolized access to reversal products, including four-factor prothrombin complex concentrates and targeted DOAC reversal antidotes. Hospitals should institute standardized order sets to eliminate administration delays in emergency and intensive care units. Third, neurosurgeons should anticipate higher operative requirements in anticoagulated patients and maintain a low threshold for decompressive interventions. Furthermore, rehabilitation specialists should recognize that anticoagulated trauma survivors possess substantial neurological recovery potential. With structured neuro-rehabilitation, these patients achieve functional milestones comparable to non-anticoagulated peers. Finally, post-acute clinicians must carefully navigate the complex decision of antithrombotic resumption. Balancing recurrent thrombotic events against secondary intracranial hemorrhage requires tailored multidisciplinary risk stratification. Ultimately, prompt resuscitation, decisive surgical care, and diligent rehabilitation ensure optimal two-year functional recovery for these vulnerable trauma patients.

Frequently Asked Questions

Do pre-injury antithrombotics increase mortality after moderate-to-severe TBI?

Current propensity-matched evidence indicates that pre-injury antithrombotics do not significantly increase overall in-hospital mortality when trauma teams utilize rapid reversal protocols. However, patients taking vitamin K antagonists consistently demonstrate higher mortality rates than those on direct oral anticoagulants or antiplatelet monotherapy, necessitating urgent correction and vigilant neurocritical monitoring.

How do functional outcomes compare between DOACs and VKAs in TBI?

Surviving patients in both direct oral anticoagulant and vitamin K antagonist cohorts achieve comparable long-term functional recovery at six months, one year, and two years post-injury. While vitamin K antagonists carry higher early mortality, survivors demonstrate equivalent functional independence on the Glasgow Outcome Scale-Extended across extended follow-up windows.

Why is emergent antithrombotic reversal critical in severe head trauma?

Emergent reversal rapidly restores normal coagulation pathways, effectively halting primary hematoma expansion and reducing secondary brain parenchymal injury. Furthermore, timely pharmacological correction allows neurosurgeons to perform urgent craniotomies or intracranial pressure monitor insertions safely, thereby mitigating secondary neurological decline and preserving the brain's long-term functional recovery potential.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Refer to the latest local and national guidelines for clinical practice.

References

1. Burwell JM et al. Two-year functional outcomes following moderate-to-severe tbi in patients on antithrombotics: Propensity-matched case-controlled study. Clin Neurol Neurosurg. 2026 Oct. doi: 10.1016/j.clineuro.2026.109573. PMID: 42431069.


2. Popma E, Davis N, West MA. Reversal of antithrombotic medications in patients with traumatic brain injury: What you need to know. J Trauma Acute Care Surg. 2025 Dec 1;99(6):828-835. doi: 10.1097/TA.0000000000004766.


3. Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al. Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage: A Statement for Healthcare Professionals from the Neurocritical Care Society and Society of Critical Care Medicine. Crit Care Med. 2016 Dec;44(12):2251-2257. doi: 10.1097/CCM.0000000000002057.